Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AKR1C3 | P42330 | 1/20 | 0.44 |
| ▸ | AKR1C1 | Q04828 | 1/20 | 0.44 |
| ▸ | NPC1 | O15118 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 1/20 | 0.41 |
| ▸ | KIF11 | P52732 | 1/20 | 0.41 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.39 |
| ▸ | PRCP | P42785 | 2/20 | 0.39 |
| ▸ | IDO1 | P14902 | 1/20 | 0.39 |
| ▸ | CCR2 | P41597 | 2/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.38 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.38 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.38 |
| ▸ | SLC18A3 | Q16572 | 5/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL5374122 | 0.98 | AKR1C3 (0.42) | AKR1C3AKR1C1NPC1RAB9AKIF11 | |
| SCHEMBL1171605 | 0.84 | SLC18A3 (0.47) | AKR1C3AKR1C1NPC1RAB9ASIGMAR1 | |
| SCHEMBL4976355 | 0.84 | SLC18A3 (0.47) | AKR1C3AKR1C1NPC1RAB9ASIGMAR1 | |
| SCHEMBL5324531 | 0.80 | — | — | |
| Hydrochloric Acid SCHEMBL16666936 | 0.78 | CPN1 (0.44) | KDM4EALDH1A1 | |
| SCHEMBL12733110 | 0.78 | GRM1 (0.47) | AKR1C3AKR1C1NPC1RAB9AKIF11 | |
| SCHEMBL17025330 | 0.75 | KCNH2 (0.48) | AKR1C3AKR1C1NPC1RAB9ASIGMAR1 | |
| SCHEMBL28171748 | 0.75 | AKR1C3 (0.47) | AKR1C3AKR1C1NPC1RAB9ASIGMAR1 | |
| SCHEMBL20838768 | 0.75 | KCNH2 (0.48) | AKR1C3AKR1C1NPC1RAB9ASIGMAR1 | |
| SCHEMBL14379229 | 0.75 | KCNH2 (0.48) | AKR1C3AKR1C1NPC1RAB9ASIGMAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030229144-A1 | Anti-epileptogenic agents | QUEEN'S UNIVERSITY AT KINGSTON | 2003-12-11 | — | — | US | claimed |
| US-20020025949-A1 | Anti-epileptogenic agents | QUEEN'S UNIVERSITY AT KINGSTON | 2002-02-28 | — | — | US | claimed |
| US-6306909-B1 | AMINOACID DERIVATIVES AND ESTERS | QUEEN'S UNIVERSITY AT KINGSTON (CA) | 2001-10-23 | — | — | US | claimed |
| JP-2001515483-A | — | — | 2001-09-18 | — | — | JP | claimed |
| EP-0969823-A2 | ANTI-EPILEPTOGENIC AGENTS | QUEEN'S UNIVERSITY AT KINGSTON (CA) | 2000-01-12 | — | — | EP | claimed |
| WO-1998040055-A2 | ANTI-EPILEPTOGENIC AGENTS | QUEEN'S UNIVERSITY AT KINGSTON (CA) | 1998-09-17 | — | — | WO | claimed |
| US-7268164-B2 | Anti-epileptogenic agents | QUEENS UNIVERSITY AT KINGSTON (CA) | 2007-09-11 | — | — | US | disclosed |
| US-6930112-B2 | Anti-epileptogenic agents | QUEEN'S UNIVERSITY AT KINGSTON (CA) | 2005-08-16 | — | — | US | disclosed |
| EP-1386166-A2 | ANTI-EPILEPTOGENIC AGENTS | QUEEN'S UNIVERSITY AT KINGSTON (CA) | 2004-02-04 | — | — | EP | disclosed |
| US-20030229144-A1 | Anti-epileptogenic agents | QUEEN'S UNIVERSITY AT KINGSTON | 2003-12-11 | — | — | US | disclosed |
| US-20030194375-A1 | Administering 3-aminopropionic acid derivative as anticonvulsant | QUEEN'S UNIVERSITY AT KINGSTON AND NEUROCHEM, INC. | 2003-10-16 | — | — | US | disclosed |
| WO-2002073208-A2 | ANTI-EPILEPTOGENIC AGENTS | QUEEN'S UNIVERSITY AT KINGSTON (CA) | 2002-09-19 | — | — | WO | disclosed |
| US-20020025949-A1 | Anti-epileptogenic agents | QUEEN'S UNIVERSITY AT KINGSTON | 2002-02-28 | — | — | US | disclosed |
| US-6306909-B1 | AMINOACID DERIVATIVES AND ESTERS | QUEEN'S UNIVERSITY AT KINGSTON (CA) | 2001-10-23 | — | — | US | disclosed |
| EP-0969823-A2 | ANTI-EPILEPTOGENIC AGENTS | QUEEN'S UNIVERSITY AT KINGSTON (CA) | 2000-01-12 | — | — | EP | disclosed |
| WO-1998040055-A2 | ANTI-EPILEPTOGENIC AGENTS | QUEEN'S UNIVERSITY AT KINGSTON (CA) | 1998-09-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030229144-A1 | Anti-epileptogenic agents | CA3, GAP43, GRIK5 | AKR1C3 1337/4885AKR1C1 1651/4885NPC1 526/4885 |
| US-20030194375-A1 | Administering 3-aminopropionic acid derivative as anticonvulsant | SLC1A2, SLC1A1, SLC1A3 | AKR1C3 349/4885AKR1C1 631/4885NPC1 1017/4885 |
| US-20020025949-A1 | Anti-epileptogenic agents | CA3, GAP43, GRIK5 | AKR1C3 1337/4885AKR1C1 1651/4885NPC1 526/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.